Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4138356 | 0.99 | CYP2D6 (0.57) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| SCHEMBL22118712 | 0.96 | CYP2D6 (0.63) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| SCHEMBL4022209 | 0.96 | CYP2D6 (0.63) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| Hydrochloric Acid SCHEMBL15264958 | 0.94 | CYP2D6 (0.62) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| SCHEMBL22529398 | 0.90 | CYP2D6 (0.55) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| SCHEMBL4160214 | 0.84 | CYP2D6 (0.50) | CYP2D6DHODHMAPTKCNH2HSD17B10 | |
| SCHEMBL15445321 | 0.80 | SIRT1 (0.57) | CYP2D6DHODHMAPTKCNH2SIRT1 | |
| SCHEMBL15451341 | 0.80 | SIRT1 (0.74) | CYP2D6DHODHSIRT1SIRT2SIRT3 | |
| SCHEMBL16258989 | 0.79 | BRD3 (0.60) | CYP2D6HSD17B10ALDH1A1SIRT1SIRT2 | |
| SCHEMBL22856853 | 0.78 | DHODH (0.62) | CYP2D6DHODHMAPTKCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| EP-1654228-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1654228-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-20 | — | — | US | disclosed |
| EP-1654228-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004110999-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | CYP2D6 1458/4885DHODH 2499/4885MAPT 4489/4885 |
| US-20090156621-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885DHODH 103/4885MAPT 1187/4885 |
| US-20060161002-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | CYP2D6 660/4885DHODH 62/4885MAPT 1102/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | CYP2D6 1458/4885DHODH 2499/4885MAPT 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.